Ligandrol (LGD-4033)


ACTIVE HALF-LIFE: 26 – 38 Hours
DOSAGE: 7.5mg/Pill



LGD 4033, acknowledged as the most potent selective androgen receptor modulator (SARM) in its category, stands out as the latest addition to the SARMs lineup, closely resembling an anabolic steroid in terms of sheer strength. Primarily designed to address acute and chronic muscle wasting conditions, cancer-related muscle loss, and age-related muscle decline, LGD 4033, or Ligandrol, originated from a medical context before gaining recognition for its athletic performance benefits.

Mechanism of Action:

Ligandrol operates by selectively binding to androgen receptors, fostering anabolic activity exclusively in bones and muscles. This targeted action avoids detrimental effects on the prostate and sebaceous glands, distinguishing it from anabolic steroids. Volunteer human studies affirm LGD 4033’s harmlessness at doses under 22 milligrams (mg) per day. Research also highlights its capacity to enhance lean muscle mass, diminish body fat, and notably amplify strength, recovery, and overall health.

Medical Applications:

Initially developed to prevent muscle wasting, LGD 4033 exhibits potential in combating cancer and assisting older individuals in maintaining muscle strength.

Athletic Benefits:

Renowned as the most powerful SARM, LGD 4033 closely rivals anabolic steroids in potency but with fewer severe side effects and suppression. This makes it particularly appealing to athletes engaging in strength-oriented sports like American football, field sports, rugby, hockey, and weightlifting. Powerlifters favor LGD for its rapid strength gains, with noticeable improvements in lifts observed at just 10mg per day over an 8-week span.

Although not widely recognized for its healing properties, LGD distinguishes itself by fortifying soft tissues rather than causing damage, making it a versatile choice for solo use or in conjunction with other SARMs and/or anabolic steroids.


LGD 4033 offers diverse stacking options catering to different athletic goals:

  1. Bulking: For optimal bulking, a solo run of LGD at 10mg per day for 8 weeks suffices, with some experienced users opting for 15 or 20mg per day. A caloric surplus and regular weight training are essential during a bulking cycle with LGD.
  2. Fat Loss: LGD at 5mg per day, coupled with standard doses of S4 Andarine and GW Cardarine, forms an effective cutting stack, preventing fat gain and aiding in obesity management.
  3. Anabolic Steroid Stack: Integrate LGD into an anabolic steroid cycle at doses ranging from 3 to 15mg per day to achieve lean muscle gains and enhanced strength.
  4. Recomping: LGD, when combined with cardarine, a strict diet, and regular cardio and weight training, facilitates simultaneous lean muscle gain and fat loss.
  5. SARMs Bridge Stack: Popularly used in a bridge with S4, LGD helps maintain gains and strength between steroid cycles. Run 3-5mg per day of LGD alongside a moderate S4 dose and HCGenerate ES. Note that LGD should not be used during post-cycle therapy (PCT).

Side Effects:

LGD 4033, while not as suppressive as anabolic steroids, is among the more potent and suppressive SARMs. Therefore, a thorough post-cycle therapy is recommended after LGD use. It is non-toxic, posing no concerns for liver issues, lipid strain, or organ damage. When used in an anabolic steroid stack, a support supplement like N2Guard is advised to mitigate potential side effects.

Half-life, Usage, and Dosage:

LGD 4033 boasts a longer half-life compared to other SARMs, spanning between 26 and 38 hours. Its potency implies that a small dose is sufficient. The standard dosage is 10mg per day over an 8-week cycle, but users may exercise discretion, adjusting doses within the range of 2 to 20mg per day. Administered orally in liquid form, LGD should be swallowed directly, followed by a chaser of juice or water, avoiding any mixture with other liquids. Holding SARMs under the tongue is unnecessary.

There are no reviews yet.

Be the first to review “Ligandrol (LGD-4033)”

Your email address will not be published. Required fields are marked *